State of integral remodeling parameters of target organs in patients with essential hypertension and obesity

M Kochueva1, V Sukhonos1, A Shalimova1

  • 1Kharkiv Medical Academy of Postgraduate Education; Sumy Outpatient hospital №3; Sumy State University, Ukraine.

Georgian Medical News
|July 15, 2014
PubMed

Insights

Obesity combined with arterial hypertension significantly impacts heart, blood vessels, and liver. This study reveals obesity exacerbates cardiovascular risks and organ damage in hypertensive patients.

Area of Science:

  • Cardiovascular Medicine
  • Metabolic Disorders
  • Organ Physiology

Background:

  • Arterial hypertension and obesity are prevalent global comorbidities.
  • Their combination intensifies target organ damage and cardiovascular risks.
  • Shared pathophysiological mechanisms include hemodynamic and neurohumoral factors.

Purpose of the Study:

  • To comparatively assess structural and functional indicators of the heart, blood vessels, and liver.
  • To investigate patients with essential hypertension (EH) stage II and normal body weight versus those with concomitant obesity (I and II degrees).

Main Methods:

  • Comparative analysis of integral indicators.
  • Assessment of cardiac, vascular, and hepatic structural and functional status.

Main Results:

  • Obesity in EH stage II patients is linked to concentric left ventricular hypertrophy with preserved ejection fraction but impaired diastolic filling.
  • Early-stage obesity in EH patients shows increased carotid intima-media thickness and arterial stiffness.
  • Hepatic parenchyma and endothelial function are impaired in hypertensive patients with obesity.

Conclusions:

  • Obesity significantly worsens structural and functional changes in target organs in patients with essential hypertension.
  • These findings highlight the critical need to manage obesity in hypertensive individuals to mitigate cardiovascular complications.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.7K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.7K
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
3.8K
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
1.7K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.7K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.6K